← All diseases Cancer

Lung cancer (non-small cell)

Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence

Search Period All yearsLast 12 monthsLast 5 years Topic All topicsGeneralNutrition and dietAlternative treatment methods Type of research Any type of researchStrongest evidence only (181)Meta-analysis (67)Treatment guideline (1)Randomized trial (51)Systematic review (37)Phase 3 study (25)Clinical trial (669)Review article (245)Early study (phase 1 or 2) (42)Case report (123)Laboratory or animal research (69)Commentary or editorial (85)Retracted publication (14) Studies Currently Seeking Participants Only (38)

Filter

Publications (2562)

• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. [Management of chronic pulmonary GVH in 2025, indication for lung transplantation (SFGM-TC)]. (2026/08/05) ♡
• Efficacy and safety of adjuvant immunotherapy after pathological complete response following neoadjuvant chemoimmunotherapy in patients with resectable NSCLC: A real-world observational study. (2026/08/05) ♡
• TSTScope Unifies Single-Cell Multi-Omics to Identify Functional T Cell States Predictive of Immunotherapy Response. (2026/08/05) ♡
• Real-world analysis of perioperative strategies for driver gene-positive resectable non-small cell lung cancer. (2026/08/04) ♡
• Post-Treatment Imaging in Lung Cancer Patients: Adherence to Surveillance Guidelines Is Associated with Improved Survival in a Longitudinal Cohort. (2026/08/04) ♡
• Long-term comparative effectiveness of tepotinib versus standard of care for MET exon 14 skipping-mutated non-small cell lung cancer. (2026/08/03) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Consensus recommendations for the management of Dato-DXd-associated adverse events in patients with advanced/metastatic NSCLC: insights from a multiregional steering committee. (2026/08/03) ♡
• Radiomic and clinical predictors of epidermal growth factor receptor mutation in stage IA non-small cell lung cancer. (2026/08/03) ♡
• Engineered tumor cell membrane-coated manganese-amplified STING nanoagonist potentiates PD-L1 blockade immunotherapy in non-small cell lung cancer. (2026/08/03) ♡
• Prognostic significance of predicted skeletal muscle index after curative-intent resection for non-small cell lung cancer. (2026/08/03) ♡
• Prognostic and Predictive Value of Peripheral CD8/PD-1/TCF-1 Positive T Cells in Non-Small Cell Lung Carcinoma Patients. (2026/08/03) ♡
• Biophysical insights into interaction mechanism of cediranib with human serum albumin: In-vitro and in-silico perspectives. (2026/08/03) ♡
• Targeting a novel metabolic vulnerability of non-small cell lung cancer to fatty acid oxidation surmounts chemoresistance. (2026/08/02) ♡
• Serum-Based Biomarker Panels are Crucial Tools for the Early Detection of Lung Cancer in High-Risk Individuals in North Indian Population. (2026/08/01) ♡
• [Malnutrition in lung cancer patients : Influence of preoperative nutritional status on the postoperative outcome in patients with non-small cell lung cancer (NSCLC) after curative surgery]. (2026/08/01) ♡
• Chronic pleural effusion one year after lung cancer surgery is associated with non-cancer mortality and postoperative nutritional decline. (2026/08/01) ♡
• Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. Efficacy and safety of immunotherapy in driver mutation-negative advanced non-small cell lung cancer: A systematic review and meta-analysis. (2026/08/01) ♡
• Health Insurance Type and Lung Cancer Stage Shift Following Coverage of Screening. (2026/08/01) ♡
• A Novel Aerogel Delivery System Reduces Drug Resistance for Non-Small Cell Lung Cancer Combination Therapy. (2026/08/01) ♡
• Calcium Phosphate Nanoparticle Delivery of siTRIB3 Inhibits EMT and Stemness in NSCLC. (2026/08/01) ♡
• 4-FPAC-Modulated Tumor-Associated Macrophage Conditioned Media Suppresses Malignant Phenotypes and Promotes Cell-Cycle Arrest and Apoptosis in NSCLC. (2026/08/01) ♡
• Sanyang Xuedai enhances radiosensitivity in human non-small cell lung cancer cells through the activation of TLR2 to increase iNOS/NO production-mediated autophagy. (2026/08/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. A Noncanonical MET Exon 14 Splice-Site Variant in Pulmonary Sarcomatoid Carcinoma With Response to Capmatinib. (2026/08/01) ♡
• Abietane-Type Diterpenoids From Salvia kiangsiensis: Isolation, Semisynthesis, and Cytotoxicity of Their Oxime Ester Derivatives. (2026/08/01) ♡
• Neurological complications induced by checkpoint inhibitors: characterising the clinical spectra. (2026/07/31) ♡
• Mycoplasma infection drives EGFR-TKI resistance through convergent transcriptomic reprogramming in non-small cell lung cancer. (2026/07/31) ♡
• Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Osthole and matrine suppress malignant progression of lead-exposed NSCLC via regulating cellular homeostasis: A combined network pharmacology and in vitro experimental study. (2026/07/30) ♡
• Novel 2-amino-4-(1H-imidazol)pyridine derivatives as potent brain-penetrant EGFR mutant inhibitors: Design, synthesis, biological evaluation, and molecular modeling study. (2026/07/30) ♡
• TFAP2A enhances radioresistance of non-small cell lung cancer by transcriptionally activating BRCA1 : TFAP2A promotes NSCLC radioresistance. (2026/07/30) ♡
• Tumor-Mimetic Microenvironment Primes Cancer Stemness and Drug Resistance through Nucleoskeleton-Mediated Chromatin Remodeling. (2026/07/30) ♡
• Exploring social determinants of health and immunotherapy utilization in patients with stage III non-small-cell lung cancer after definitive chemoradiation. (2026/07/30) ♡
• Phenylalanine- and tryptophan-based hydrazone hybrids targeting the VEGF axis and caspase-mediated apoptosis: Design, synthesis, and biological evaluation. (2026/07/28) ♡
• Immunological biomarkers for precision stereotactic body radiation therapy in early-stage non-small cell lung cancer: a systematic review. (2026/07/24) ♡
• A novel multivariate framework for functional gene networks enrichment analysis. (2026/07/24) ♡
• A novel photosensitizer (hE26) for photodynamic therapy enhances anticancer efficacy via reactive oxygen species-induced mitochondrial apoptosis in non-small cell lung cancer. (2026/07/24) ♡
• Transitioning from multiport to uniport robot-assisted thoracic surgery: a propensity score-weighted evaluation of safety and feasibility. (2026/07/24) ♡
• Functional restoration of conformational (R175H) and contact (R273H) mutant p53 by Bacillus-derived Hydroxymycotrienin A in non-small cell lung cancer: a computational approach. (2026/07/24) ♡
• Genetic landscape features associated with PD-L1 expression status in advanced lung adenocarcinoma: a targeted sequencing analysis. (2026/07/23) ♡
• Cost-effectiveness analysis of combined immunotherapy regimens for non-squamous non-small lung cancer after tyrosine kinase inhibitors resistance. (2026/07/23) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Editorial: Liquid biopsy in non-small cell lung cancer for diagnosis, treatment selection and monitoring. (2026/07/23) ♡
• Oncolytic adenovirus armed with cGAS activates STING pathway and enhances antitumor immunity in lung cancer with superior combined efficacy of PD-L1 therapy. (2026/07/23) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Microbiome as a prediction of immunotherapy response in lung cancer. (2026/07/23) ♡
• Integrated cellular, proteomic and metabolomic profiling of immune-related adverse events in non-small cell lung cancer. (2026/07/23) ♡
• A single-cell sequencing-based prognostic model reveals HLA-DRA, NPC2, and PRPF38B as immune-regulatory tumor suppressors in non-small cell lung cancer. (2026/07/23) ♡
• Systematic reviewiAll research on one question is searched according to fixed rules and compared side by side, so that no studies with poor outcomes are missed. Association between prognostic nutritional index and prognosis in non-small cell lung cancer patients receiving PD-1/PD-L1 inhibitors: a meta-analysis. (2026/07/23) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Redefining the concept of resectability in the landscape of perioperative treatments for lung cancer. (2026/07/22) ♡
• Clinicopathological correlations of perineural invasion in resected non-small cell lung cancer. (2026/07/22) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Case Report: Exceptional survival with immunotherapy in a patient with EGFR exon 20 insertion (p.S768_D770dup) and high PD-L1 expression. (2026/07/22) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Cancer-associated fibroblasts in the lung cancer microenvironment from multi-dimensional mechanisms to therapeutic strategies. (2026/07/22) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Durable response to ALK inhibition in low-allele-frequency SPTBN1-ALK-rearranged gastric cancer followed by lineage plasticity-mediated resistance: a case report. (2026/07/21) ♡

↑ Back to top

codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.